Could a malaria drug help fight HPV in women with HIV?
NCT ID NCT06519994
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a vaginal insert containing artesunate, a malaria drug, could help clear HPV after standard cervical precancer treatment in women living with HIV. 120 women in Kenya used the insert or a placebo for 5 nights on and off over 6 weeks. The goal was to see if the drug improved HPV clearance and was safe and easy to use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL PRECANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Lumumba Sub-County Hospital KEMRI- Research Care Training Program (RCTP) Building
Kisumu, 614-40100, Kenya
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Walking groups could shield HIV-Positive latino men from heart disease
- Friends helping friends: a novel social-network strategy to boost HIV prevention
- Decade-Long study aims to unlock liver disease risks in HIV-Hepatitis b patients
- Could HIV and age weaken vaccine protection? study investigates
- Massive HIV database could unlock secrets of Long-Term health
- Double probe heat therapy may slash cervical cancer risk in HIV-positive women